HCPLive

02/09/2025

🚨 New ACP guidelines favor cost-effective meds over pricey newer options, with beta-blockers, valproate, venlafaxine, & amitriptyline recommended first.

Read more:

New ACP migraine guidelines recommend β-blockers, valproate, venlafaxine, or amitriptyline for episodic migraine prevention before using CGRP-targeting drugs.

02/09/2025

Our next is coming soon, but in the meantime you can catch up on previous episodes, including this deep dive into the PARASOL program and with Drs. Brendon Neuen and Shikha Wadhwani.

Check it out here: https://www.hcplive.com/view/kidney-compass-future-of-parasol-fsgs-management

02/09/2025

CSL announced a one-time infusion of etranacogene dezaparvovec-drlb (HEMGENIX) gene therapy demonstrated long-term sustained efficacy and safety in adults with hemophilia B over 4 years in the pivotal Phase 3 HOPE-B study.

🔗 https://www.hcplive.com/view/hemophilia-b-gene-therapy-achieves-sustained-benefit-over-4-years

02/08/2025

GLP-1RA use is associated with significant clinical benefits, including a reduced risk of alcohol-related liver disease, lower rates of hepatic decompensation, and improved survival in patients with alcohol use disorder and type 2 diabetes.

Learn more:

GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.

02/08/2025

In a new study, findings indicate that drug survival among patients with at the 12 and 24-month marks is highest for , followed by upadacitinib and then by tralokinumab.

However, biologic- and JAK-naïve patients saw comparable drug survival rates with dupilumab and upadacitinib.

Learn: https://www.hcplive.com/view/dupilumab-survival-compared-to-upadacitinib-tralokinumab-atopic-dermatitis

02/08/2025

🌟 ADP101 oral immunotherapy raised thresholds in kids but missed its primary endpoint. High-dose ADP101 showed promise (55% tolerated ≥ 600 mg challenge dose) vs. placebo (20%).

Read more:

ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.

02/08/2025

ICYMI: Data from offer insight into the effects of obinutuzumab in active lupus nephritis.

Learn more: https://www.hcplive.com/view/regency-obinutuzumab-proves-efficacy-in-lupus-nephritis

02/08/2025

New tool helps parents manage kids’ . 🥜🚫🍎 The PSED-FA scale assesses parental confidence in meal prep, nutrition, & school communication with high reliability.

Read more about the study:

Investigators in Korea developed and validated PSED-FA, a reliable tool to assess parental confidence in managing children's food allergies and nutrition.

02/08/2025

Dupilumab reduced moderate or severe exacerbations compared to placebo in phase 3 trials, showing significant clinical efficacy and safety.

Read more:

Approved under the name Dupixent in September 2024, the biologic is the first of its kind approved for COPD.

02/07/2025

Novo Nordisk announced an interim analysis of the Phase 3 FRONTIERS3 trial showing the tolerability and efficacy of once-weekly Mim8 prophylaxis for children living with hemophilia A with and without inhibitors.

🔗 https://www.hcplive.com/view/mim8-prophylaxis-tolerable-for-children-with-hemophilia-a-in-phase-3-analysis

02/07/2025

Results from the VIVID-2 open-label extension study of mirikizumab-mrkz (Omvoh) in patients with moderately to severely active Crohn's disease highlight the IL-23p19 antagonist’s impact on long-term clinical and endoscopic outcomes.

Learn more: https://www.hcplive.com/view/vivid-2-mirikizumab-omvoh-shows-long-term-efficacy-crohn-disease

02/07/2025

Perceived stress was positively correlated with symptom burden in people with fibromyalgia syndrome even when not associated with endocrinological stress indicators, according to new research.

Learn more: https://www.hcplive.com/view/perceived-stressed-associated-symptom-burden-people-fibromyalgia

Endocrinological stress indicators were not associated with perceived stress, which was related to symptom severity.

02/07/2025

Tonix Pharmaceuticals announced positive topline data from its phase 1, single ascending dose trial demonstrating the safety, tolerability, pharmacokinetics, and pharmacodynamics of TNX-1500 in healthy participants.

Learn more: https://www.hcplive.com/view/tonix-announces-positive-topline-phase-1-data-for-tnx-1500

02/07/2025

Positive 6-month data from the Phase 2 VERONA trial evaluating the vorolanib intravitreal insert (DURAVYU) reported a meaningful improvement in vision and anatomy in eyes with diabetic macular edema (DME).

🔗 https://www.hcplive.com/view/duravyu-hits-primary-phase-2-endpoint-reduces-treatment-burden-in-dme

02/06/2025

Novel rhinoconjunctivitis phenotypes in children with may not be solely allergy-driven, challenging conventional classifications.

Read more:

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conferen...

02/06/2025

Watch Dr. Susheel Kodali, director of the Structural Heart and Valve Center at NewYork-Presbyterian and Columbia, discuss an innovative transcatheter therapy for tricuspid regurgitation (TR) that is providing a new treatment option to vastly improve patient's quality of life. Learn more: https://bit.ly/4j3f6lg

02/06/2025

Propranolol significantly reduces ischemic risk in females with non-aura , according to a new study from Vanderbilt University and All of Us Research.

Learn more:

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

02/06/2025

New pivotal phase 3 findings have been announced by LEO Pharma regarding delgocitinib (Anzupgo) 20mg/g cream for the treatment of chronic hand (CHE) among adolescents aged 12-17 years.

The February 4 announcement followed the pivotal DELTA TEEN trial, during the topical pan-JAK inhibitor was evaluated for teenage patients who have not responded adequately to or cannot implement topical corticosteroids.

Learn: https://www.hcplive.com/view/delgocitinib-effective-chronic-hand-eczema-teens-pivotal-phase-3-findings